A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases

StatusNot Yet Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Sjögren's disease (SjD).
Trial Details
NCT Number NCT07873931
Lead Sponsor Bristol-Myers Squibb
Conditions
(from sponsor)		 Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Lupus Nephritis
Related terms Arthritis, Rheumatoid, Autoimmune Diseases, Dermatomyositis, Dry Eye Syndromes, Lung Diseases, Interstitial, Lupus Erythematosus, Systemic, Lupus Nephritis, Myositis, Scleroderma, Diffuse, Scleroderma, Systemic, Sjogren's Syndrome
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov